Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Blood (2016) 128 (22): 4208.

https://doi.org/10.1182/blood.V128.22.4208.4208

Published: 2016

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Nathan H. Fowler, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Maria A. Rodriguez, MD, Barbara Pro, MD, F.B. Hagemeister, MD, Anas Younes, MD, Jatin J Shah, MD, Larry W Kwak, MD, PhD, Diana Rodriguez, Peter McLaughlin, MD

Blood (2011) 118 (21): 99.

https://doi.org/10.1182/blood.V118.21.99.99

Published: 2011

Journal Articles

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Bouthaina S. Dabaja, MD, Jack Phan, MD PhD, L. Jeffrey Medeiros, MD, F.B. Hagemeister, MD, Hubert Chuang, MD, Luis Fayad, MD, Ferial Shihadeh, MD, Pamela Allen, PhD, Christine Wogan, MS, Maria A. Rodriguez, MD

Blood (2011) 118 (21): 2695.

https://doi.org/10.1182/blood.V118.21.2695.2695

Published: 2011

Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D

Blood (2008) 112 (11): 835.

https://doi.org/10.1182/blood.V112.11.835.835

Published: 2008

Journal Articles

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD, Sattva Neelapu, MD, Michelle Fanale, MD, Maria Rodriguez, MD, Ana Ayala, RN, Barbara Pro, M.D., F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, Larry W. Kwak

Blood (2008) 112 (11): 3056.

https://doi.org/10.1182/blood.V112.11.3056.3056

Published: 2008

Journal Articles

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Xiao Zhou, MD, Auris Huen, Pharm, Shyam Teegala, MD, Yuan Ji, MD, Luis Fayad, MD, F.B. Hagemeister, MD, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 3993.

https://doi.org/10.1182/blood.V110.11.3993.3993

Published: 2007

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Michael A. Thompson, MD, PhD, Auris Huen, PharmD, Gregory D. Ayers, MS, Bela B. Toth, DDS, Rena V. Sellin, MD, Ana O. Hoff, MD, William A. Murphy, Jr., MD, F.B. Hagemeister, MD

Blood (2006) 108 (11): 4607.

https://doi.org/10.1182/blood.V108.11.4607.4607

Published: 2006

Journal Articles

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

Felipe Samaniego, MD, Luis E. Fayad, MD, Barbara Pro, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Sattva Neelapu, MD, Anas Younes, MD, Larry W. Kwak, MD

Blood (2006) 108 (11): 4722.

https://doi.org/10.1182/blood.V108.11.4722.4722

Published: 2006

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 4103.

https://doi.org/10.1182/blood.V108.11.4103.4103

Published: 2006

Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 3994.

https://doi.org/10.1182/blood.V108.11.3994.3994

Published: 2006

Journal Articles

Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.

Luis Fayad, MD, Michael Overman, MD, Barbara Pro, MD, Peter McLaughlin, MD, Felipe Samaniego, MD, Anas Younes, MD, Jorge Enrique Romaguera, MD, F.B. Hagemeister, MD, Larry Kwak, MD, Maria Alma Rodriguez, MD

Blood (2006) 108 (11): 2770.

https://doi.org/10.1182/blood.V108.11.2770.2770

Published: 2006

Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Gerald S. Falchook, MD, Richard Champlin, M.D., F.B. Hagemeister, M.D., Chitra Hosing, M.D., Larry W. Kwak, M.D., Susan O’Brien, M.D, Maria Alma Rodriguez, M.D., Srdan Verstovsek, M.D., Barbara Pro, M.D.

Blood (2006) 108 (11): 2460.

https://doi.org/10.1182/blood.V108.11.2460.2460

Published: 2006

Journal Articles

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

F.B. Hagemeister, MD, P. McLaughlin, MD, L. Fayad, MD, F. Samaniego, MD, N. Dang, MD, A. Goy, MD, J. Romaguera, MD, B. Pro, MD, V. Beasley, R.N., F. Cabanillas, MD, M. Rodriguez, MD

Blood (2005) 106 (11): 941.

https://doi.org/10.1182/blood.V106.11.941.941

Published: 2005

Journal Articles

ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease

J. Rodriguez, M.A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A. Sarris, J. Romaguera, B. Andersson, F. Cabanillas, F.B. Hagemeister

Blood (1999) 93 (11): 3632–3636.

https://doi.org/10.1182/blood.V93.11.3632

Published: 1999

Journal Articles

Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features

J. Rodriguez, P. McLaughlin, F.B. Hagemeister, L. Fayad, M.A. Rodriguez, M. Santiago, M. Hess, J. Romaguera, F. Cabanillas

Blood (1999) 93 (7): 2202–2207.

https://doi.org/10.1182/blood.V93.7.2202

Published: 1999

NARROW

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease

Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only